Matinas BioPharma (MTNB) News Today → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Free MTNB Stock Alerts $0.18 0.00 (0.00%) (As of 04/29/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMatinas Declines on Public Offeringmsn.com - April 3 at 1:52 PMMatinas BioPharma Prices $10 Million Registered Direct Offeringglobenewswire.com - April 3 at 8:30 AMMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 1 at 3:38 PMMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2023 Financial Results and Provides a Business Updatefinanznachrichten.de - March 28 at 5:11 PMMatinas BioPharma (NYSEAMERICAN:MTNB) Issues Earnings Resultsmarketbeat.com - March 28 at 9:18 AMQ4 2023 Matinas BioPharma Holdings Inc Earnings Callfinance.yahoo.com - March 28 at 7:33 AMMTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023investorplace.com - March 27 at 11:03 PMMatinas BioPharma Reports 2023 Financial Results and Provides a Business Updateglobenewswire.com - March 27 at 4:05 PMMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulationfinanznachrichten.de - March 25 at 10:12 AMMatinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulationglobenewswire.com - March 25 at 8:00 AMWhy Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?finance.yahoo.com - March 22 at 3:59 PMThree Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Responsefinance.yahoo.com - March 22 at 10:59 AMThree Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Responseglobenewswire.com - March 22 at 9:15 AMMatinas BioPharma Regains Compliance with NYSE American Continued Listing Standardsglobenewswire.com - March 22 at 6:30 AMMatinas BioPharma (MTNB) to Release Quarterly Earnings on Wednesdaymarketbeat.com - March 12 at 7:35 AMMatinas BioPharma Holdings, Inc. (MTNB)uk.finance.yahoo.com - March 3 at 12:03 AMMatinas BioPharma Holdings Inc.wsj.com - February 28 at 7:49 AMMatinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolutionfinance.yahoo.com - February 26 at 8:27 AMMatinas BioPharma Hldgs Stock (AMEX:MTNB) Dividends: History, Yield and Datesbenzinga.com - February 23 at 7:18 AMMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosisfinance.yahoo.com - February 20 at 8:14 AMMatinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosisglobenewswire.com - February 20 at 7:30 AMAVBP ArriVent BioPharma, Inc.seekingalpha.com - February 4 at 7:38 AMMatinas BioPharma Holdings Inc MTNBmorningstar.com - January 21 at 3:21 AMMatinas BioPharma to Present at Biotech Showcase 2024finance.yahoo.com - January 3 at 8:41 AMMatinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotidesfinance.yahoo.com - December 27 at 8:07 AMMatinas BioPharma Holdings, Inc.: Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDAfinanznachrichten.de - December 21 at 9:15 AMMatinas BioPharma Plans To Meet With FDA In Q1 To Finalize Phase 3 Protocol For MAT2203markets.businessinsider.com - December 21 at 8:25 AMMatinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDAfinance.yahoo.com - December 21 at 8:25 AMMatinas BioPharma Hldgs Stock (AMEX:MTNB), Guidance and Forecastbenzinga.com - December 20 at 11:55 PMAnalysts Offer Insights on Healthcare Companies: Bolt Biotherapeutics (BOLT), Matinas BioPharma (MTNB) and Vor Biopharma (VOR)markets.businessinsider.com - November 11 at 12:29 AMAnalysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Shattuck Labs (STTK) and Matinas BioPharma (MTNB)markets.businessinsider.com - November 10 at 7:53 PMMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 10 at 2:20 PMQ3 2023 Matinas BioPharma Holdings Inc Earnings Callfinance.yahoo.com - November 9 at 9:22 AMMatinas BioPharma Holdings Inc (MTNB) Reports Q3 2023 Financial Results and Business Progressfinance.yahoo.com - November 8 at 7:34 PMMatinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Updatefinance.yahoo.com - November 8 at 5:54 PMMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Modelfinanznachrichten.de - November 7 at 8:17 AMMatinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Modelfinance.yahoo.com - November 7 at 8:17 AMMatinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023finance.yahoo.com - November 1 at 8:00 AMBTIG Reiterates Matinas Biopharma Holdings (MTNB) Buy Recommendationmsn.com - October 13 at 7:36 AMMatinas BioPharma Shares Double After Patient Achieves Clinical Resolutionmarketwatch.com - October 11 at 2:28 PMBiotech Catches Massive Premarket Bidtheglobeandmail.com - October 11 at 2:28 PMMatinas BioPharma stock soars 80% on antifungal drug updatemsn.com - October 11 at 11:52 AMPatient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolutionfinance.yahoo.com - October 11 at 7:58 AMMatinas BioPharma to Present at Two Investment Conferences in October 2023finance.yahoo.com - September 28 at 7:36 AMMatinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeekfinance.yahoo.com - September 27 at 8:23 AMMatinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiencyfinanznachrichten.de - September 23 at 7:00 AMMatinas BioPharma Announces Notification of NYSE American Continued Listing Deficiencyfinance.yahoo.com - September 22 at 5:37 PMMatinas BioPharma to Participate in the H.C. Wainwright Global Investment Conferencefinance.yahoo.com - September 6 at 7:38 AMMatinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseasesfinance.yahoo.com - August 22 at 7:41 AMMatinas BioPharma Holdings, Inc.: Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Updatefinanznachrichten.de - August 11 at 4:00 PM Get Matinas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address Massive breakthrough for options traders. (Ad)A 34 year old man from central florida has uncovered a totally new way to trade options… Already this year it’s allowed real people to capture top returns of 50%... 100%... Even 200% overnight… Without using technical patterns, momentum, A.I. or any of the other commonly used strategies… Now, it’s important to mention that nothing is 100% perfect in terms of trading. Click here to see this stunning development for yourself. MTNB Media Mentions By Week MTNB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MTNB News Sentiment▼0.000.34▲Average Medical News Sentiment MTNB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MTNB Articles This Week▼01▲MTNB Articles Average Week Get Matinas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MRKR News PMN News JAN News CARA News OCUP News UNCY News BCTX News BOLT News XLO News NXTC News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:MTNB) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe AI stock to buy right nowStockEarningsGlobal crypto currency reset (41 major banks signed up)Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Matinas BioPharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
